{"id":"alvelestat-oral-tablet-dose-1","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"By inhibiting neutrophil elastase, alvelestat aims to reduce inflammation and tissue damage in the lungs, which is particularly relevant in conditions such as alpha-1 antitrypsin deficiency-associated lung disease and acute respiratory distress syndrome.","oneSentence":"Alvelestat is a selective inhibitor of neutrophil elastase, an enzyme involved in the degradation of lung tissue.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T04:08:38.680Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Alpha-1 antitrypsin deficiency-associated lung disease"},{"name":"Acute respiratory distress syndrome"}]},"trialDetails":[{"nctId":"NCT04539795","phase":"PHASE1, PHASE2","title":"COVID-19 Study of Safety and Tolerability of Alvelestat","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2021-01-25","conditions":"Covid19","enrollment":15},{"nctId":"NCT03636347","phase":"PHASE2","title":"A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo.","status":"COMPLETED","sponsor":"Mereo BioPharma","startDate":"2018-10-29","conditions":"Alpha 1-Antitrypsin Deficiency, Emphysema, COPD","enrollment":99},{"nctId":"NCT04396067","phase":"PHASE2","title":"Aerosol Combination Therapy of All-trans Retinoic Acid and Isotretinoin as A Novel Treatment for Inducing Neutralizing Antibodies in COVID -19 Infected Patients Better Than Vaccine : An Innovative Treatment","status":"UNKNOWN","sponsor":"Kafrelsheikh University","startDate":"2020-10","conditions":"COVID-19","enrollment":360}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["MPH966"],"phase":"phase_2","status":"active","brandName":"Alvelestat oral tablet - dose 1","genericName":"Alvelestat oral tablet - dose 1","companyName":"Mereo BioPharma","companyId":"mereo-biopharma","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Alvelestat is a selective inhibitor of neutrophil elastase, an enzyme involved in the degradation of lung tissue. Used for Alpha-1 antitrypsin deficiency-associated lung disease, Acute respiratory distress syndrome.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}